World Lung Cancer Day: A Glimpse Into Hope for the Future
Expert Perspectives · Keira Smith · 2024-08-01
In honor of World Lung Cancer Day on August 1, OncData Editorial Board and Fellows Forum members Samuel Kareff, Beth Sandy, and Morana Vojnic sat down for a conversation on all things lung cancer, including:
- The importance of molecular testing in order for patients to receive targeted therapy, particularly for patients with non–small cell lung cancer (NSCLC)
- Recent approvals of alectinib, tarlatamab, and other targeted therapies that have impacted treatment and outcomes
- Updates on lung cancer clinical trials presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
- Advances in rarer subtypes, such as mesothelioma
- The importance of provider and patient education
- Reasons for hope for the future offered by the myriad of developments and research advances in the pipeline
- And more!
About the Speakers
Samuel Kareff, MD, MPH, is a Medical Oncologist and the Outgoing Chief Hematology-Oncology Fellow at the University of Miami’s Sylvester Comprehensive Cancer Center and Jackson Memorial Hospital in Florida. He is soon to enter hybrid practice focusing on thoracic and gastrointestinal cancers. Dr. Kareff has special research interests in health advocacy, public policy, and the development of cancer therapies.
Beth Sandy, MSN, CRNP, is an Outpatient Thoracic Oncology Nurse Practitioner at the University of Pennsylvania Abramson Cancer Center in Philadelphia, Pennsylvania. She specializes in the treatment and supportive care of patients with lung cancer and other thoracic malignancies. Ms. Sandy has authored and coauthored numerous peer-reviewed publications, posters, and book chapters, and has been a speaker at several national and international conferences. She is a member of several professional societies and is active on committees and editorial boards for APSHO, IASLC, MASCC, ONS, and SITC.
Morana Vojnic, MD, MBA, is an Assistant Professor of Medicine in the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health and a Medical Oncologist at Lenox Hill Hospital, where she serves as Director of Oncologic Services in the Brain and Spine Metastases Program. She specializes in thoracic and neuro-oncology, with expertise in the treatment of lung cancer, mediastinal tumors, head and neck cancer, brain cancer, and metastatic lesions of the brain and spine. With a background in molecular genetics, Dr. Vojnic designs personalized treatment plans and protocols using targeted drugs, immunotherapy, and chemotherapy for the treatment of patients with these diseases.